Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791354 | 0.90 | GAA (0.35) | CYP3A4ADRB3ADRA2BADRA2CCTSD | |
| SCHEMBL3791353 | 0.90 | GAA (0.35) | CYP3A4ADRB3ADRA2BADRA2CCTSD | |
| SCHEMBL13082463 | 0.90 | CYP3A4 (0.34) | CYP3A4ADRB3ADRA2BADRA2CGAA | |
| SCHEMBL13788183 | 0.86 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CGAA | |
| SCHEMBL3787926 | 0.84 | CYP3A4 (0.34) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL3787929 | 0.84 | CYP3A4 (0.34) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL12784423 | 0.84 | GAA (0.34) | CYP3A4CTSDGAA | |
| SCHEMBL13082688 | 0.83 | CYP3A4 (0.34) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL8243274 | 0.82 | ADRB3 (0.44) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL12349810 | 0.81 | ADRB3 (0.41) | CYP3A4ADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | CYP3A4 755/4885ADRB3 4531/4885ADRA2B 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.